33 results about "Isoflurane" patented technology

A method of calculating the flux of any gas (x) in a CBC circuit for a ventilated or a spontaneous breathing subject, for example said gas(x) being; a) an anesthetic such as but limited to; i)N₂O; ii) sevoflurane; iii) isoflurane; iv) halothane; v) desflurame; or the like b) Oxygen; c) Carbon dioxide; or the like utilizing the following relationships; Flux of gas(x)=SGF (F_SX−F_EX) wherein SGF=Source of gas flow into the breathing circuit (CBC circuit) in liters/minute as read from the gas flow meter as set by the anesthesiologist; F_SX=Fractional concentration of gas X in the source gas (which is set by the anesthesiologist); F_EX=Fractional concentration of gas X in the end expired gas as determined by a portable gas analyzer, or the like.

The invention relates to an organic composition, in particular to non-aqueous electrolyte of a lithium ion battery and a lithium ion secondary battery manufactured by using the same. The non-aqueous electrolyte comprises annular carboxylic ester, annular sulfite, electrolyte salt and isoflurane shown in the following structural formula: Rf1-O-Rf2, wherein Rf1 represents a fluorine-containing alkyl group with 3-4 carbon atoms, and Rf2 represents a fluorine-containing alkyl group with 2-5 carbon atoms. The mass percent of the isoflurane in the electrolyte is 10-50%. The non-aqueous electrolyte also comprises fluorocarbon surfactant so as to further improve the battery performance. The non-aqueous electrolyte can greatly improve the safety performance of the lithium ion battery and obviously improve the electrochemical performance such as cycle performance as well as the high-temperature conservation performance of the lithium ion battery.

The invention relates to a method for establishing a pseudomonas aeruginosa infectious pneumonia animal model. The method comprises the following steps: 1) deeply anesthetizing a mouse by adopting isoflurane; and 2) dripping nose of the mouse with pseudomonas aeruginosa, so that a pseudomonas aeruginosa infectious pneumonia model is established. The method provided by the invention has the advantages that the mouse can be effectively infected, and the pseudomonas aeruginosa pneumonia model is successfully established; and the mouse model after infection is stable and can be applied to evaluation of vaccines and research of protective mechanisms.

The invention relates to a preparation method of silicosis mouse models. The preparation method of the silicosis mouse models is characterized in that after experiment preparation, isoflurane in an anesthesia machine is adopted to anesthetize mice in a model group, 3 seconds after rapid-shallow breaths of the mice become deep and slow, each mouse is taken out and placed at the center of a palm, the tip of a thumb presses against the underjaw of each mouse, a micropipette is adopted to instill a SiO2 micro-sized particle suspension through the nose of each mouse, the SiO2 micro-sized particle suspension is instilled into the nose wings to be absorbed, closed-chest massage is conducted for 2-3 minutes, then the mice are placed into cages, and after an experiment is finished, the mice are sent back to a normal-temperature animal feed room; only normal saline of the same volume is used for conducting nasal inhalation on mice in a contrast group; weight indexes of the mice are obtained before and after the experiment, the mice are killed at the first week, the second week, the fourth week, the eighth week and the sixteenth week respectively, lung tissue is taken to be pathologically andbiochemically compared and identified, and a model preparation effect is evaluated. According to the preparation method of the silicosis mouse models, a model production technology is stable and efficient; the method can be repeated many times and is noninvasive, environmentally friendly and humanistic, and labor and time are saved.

The invention belongs to the technical field of small animal anesthesia and relates to a simple economical small animal inhalation anesthesia machine which comprises a gas steel bottle, a gas adjusting valve, a three-way pipe I, a gas flow meter I, a gas flow meter II, an isoflurane gas volatilization bottle, a three-way pipe II, an adjustable three-way pipe, an anaesthetic mask, an animal body constant temperature system, an anesthesia induction box and a gas recycling bottle. The gas steel bottle is connected with the gas adjusting valve, the three-way pipe I, the gas flow meter I, the gas flow meter II, the isoflurane gas volatilization bottle, the three-way pipe II, the adjustable three-way pipe, the anaesthetic mask, the animal body constant temperature system, the anesthesia induction box and the gas recycling bottle in sequence. Using results show that the simple economical small animal inhalation anesthesia machine is simple and reasonable in structure, various parts are fixed and combined in a coordinating mode, small animals can be subjected to anesthesia control in short time or long time, accurate anesthesia depth is guaranteed, safety is good, after operation, the morbidity and the mortality of the small animals are low, and the operation success rate is high.

The invention relates to a preparation method of myocardial ischemia/reperfusion model in rats. The preparing method comprises the following steps in turn: I, anesthetizing, namely placing rats in an induction box, performing inhalation anesthesia by using 2 to 3 percent isoflurane, taking the rats out of the induction box, allowing the rats to continuously inhale isoflurane under a mask to maintain anesthesia; II, cutting off the chest skin and extruding the heart, disinfecting the chest skin, cutting off the chest skin, expanding the subcutaneous muscle to enter the chest, and directly extruding the heart out of the intercostals; III, ligating the left anterior descending coronary artery, ligating a starting end of the left anterior descending coronary artery by using a slipknot, sending the heart back to the chest after ligation, making one end of the ligating line positioned out of the chest, sewing and closing the chest; and IV, loosening the ligating line after ischemia is finished, directly loosening the ligating line exposed out of the chest, and restoring blood supply in the coronary. The invention is simple in operation, short in time consumption and relatively high in survival rate of the rats.

A process for preparing isolfuothane from trifluoroethanol, N-methypyrrolidone and freon-22 includes such steps as etherifying and chloridizing.

The invention provides a coating composition, a coating piece prepared from the coating composition, a preparation method of the coating piece and a domestic appliance applying the coating piece. Thecoating composition is prepared from polysilazane and fumed silica. The chemical structure of polysilazane is as shown in the description, wherein at least one of R1, R2 and R3 is a low surface energygroup, and the low surface energy group is hydrogen, siloxy, alkyl siloxy, perfluoroalkyl or alkyl isoflurane. The coating piece prepared from the coating composition has the advantages that the hardness is high, the adhesiveness is good, the temperature resistance is good, cleaning can be done easily, the food contact safety level can be reached.

The invention relates to a liver acellular stent construction method based on an irreversible electroporation technology. The method comprises the following steps of 1.1) weighing a rat, carrying outgas inhalation anesthesia by using isoflurane, maintaining the gas inhalation anesthesia, after the anesthesia is effective, disinfecting abdominal skin of the SD rat in a supine position by using 75%alcohol, and opening the abdomen layer by layer to expose the liver; 1.2) clamping a left lateral lobe area of the rat liver by using a caliper type electrode, and performing high-voltage pulsed electric field treatment; 1.3) after the irreversible electroporation treatment is finished, performing transhepatic portal vein catheterization, perfusing with heparinized PBS (Phosphate Buffer Solution), cutting off the subhepatic inferior vena cava until the liver is full and the color is gradually lightened, gradually dissociating tissues and ligaments around the liver, taking down the liver, andimmersing the liver into the heparinized PBS; 1.4) putting the taken liver into a clean container, and performing one-way perfusion with deionized water, and 1.5) after the deionized water perfusion is finished, performing one-way perfusion with PBS for 30 minutes to complete the preparation of the stent. By the method disclosed by the invention, the construction efficiency of the in-vitro acellular stent can be effectively improved under the condition of not applying harmful chemical preparations.

The invention discloses a construction method of a mouse ventricular aneurysm model, comprising the following steps: anesthetizing a mouse by inhaling isoflurane without mechanical ventilation; forming a small skin incision in the left chest to expose the intercostal space of the most violent cardiac beating after the mouse enters a relaxed state and does not have respiratory depression and dysphoria; forming a small hole between the ribs by using tissue forceps and hemostatic forceps, opening the pleura and pericardium, and slightly extruding the thorax of the mouse; ligating at a position 4-4.5 mm away from the origin of the coronary artery by adopting an absorbable 6-0 suture; ligating the left anterior descending branch and the half myocardium together; immediately putting the heart into the thoracic cavity after ligation, manually exhausting, and suturing and knotting. According to the method, a simple, repeatable and stable mouse ventricular aneurysm model can be manufactured, the model forming rate is high, the method can be used for researching before ventricular aneurysm formation and researching the internal mechanism of mouse ventricular aneurysm formation under different strains and in different states, and a theoretical basis is provided for treatment and prevention of ventricular aneurysm.

The invention discloses a synthesis method of (1-chloro-2,2,2-trifluoroethyl)-difluoromethyl ether (isoflurane, whose structure is as the right figure), belonging to the field of pharmaceutical chemicals. The method takes (2,2,2-trifluoroethyl)-difluoromethyl ether (etherate) as starting material and comprises the following steps of: adding a right amount of water to the etherate; introducing chlorine for chlorination to obtain a mixture of isoflurane, a few impurities and unreacted etherate; carrying out fractionation to obtain the crude isoflurane; reducing the main impurity (1,1-dichloro-2,2,2-trifluoroethyl)-difluoromethyl ether by isopropanol under the sun light to obtain the azeotrope of the isoflurane and the acetone again; combining the collected crude isoflurane and the azeotrope; adding the acetone and carrying out distillation purification to obtain the isoflurane. The method has easy quality control, high yield, low cost and safe and convenient operation and is suitable for industrial production.

The invention belongs to veterinary medicine preparation technology and provides an emulsified isoflurane compound anesthetic for dogs and a preparation method thereof. The emulsified isoflurane compound anesthetic for the dogs is formed by isoflurane, citric acid fentanyl citrate, lidocaine hydrochloride and 30% of fat emulsion. The isoflurane, the citric acid fentanyl citrate and the lidocaine hydrochloride are dissolved in the 30% of fat emulsion and then potted and sealed in ampoule bottles, after full oscillation, water bath and sterilization, the emulsified isoflurane compound anesthetic for the dogs is obtained. The anesthetic is rapid in anesthesia induction, safe and effective in the process of anesthesia, strong in anesthesia controllability, small in toxic and side effects, convenient to use, and especially suitable for complex operations or long-time operations, and the dogs can revive rapidly.

The invention belongs to the technical field of textile assistants and discloses a scouring agent for short-process pretreatment. The scouring agent contains the following components in parts by weight: 12-20 parts of sodium dodecyl benzene sulfonate, 1-4 parts of nonyl phenol, 0.9-10 parts of isoflurane, 1-1.5 parts of pethidine, 5-7 parts of acrylate, 10-15 parts of acrylonitrile, 12-14 parts of polymethylhydrosiloxane, 1-12 parts of diethylpropanediol and 90-150 parts of ethanol. The invention also discloses a method for preparing the scouring agent, application of the scouring agent in a desizing/scouring one-step process of cotton-polyester blended fabrics, in a desizing/scouring-bleaching two-step process of pure cotton fabrics and a cold pad-batch process of cotton-polyester blended fabrics, and further discloses a technological process of the process and a padding liquid formula. The scouring agent disclosed by the invention is rapid in penetration, high in emulsifying capacity, high in detergent washing capacity, high-temperature-resistant, oxidant-resistant, wide in application range and good in treatment effect.

The invention discloses a pharmaceutical composition for local anaesthesia. The pharmaceutical composition comprises the following components in proportion: 0.5-2 parts of QX-314, 0.25-2 parts of nanogold, 0.5-4 volume parts of isoflurane. The invention further discloses a preparation method and application of the pharmaceutical composition for local anaesthesia. The composition disclosed by the invention has good anesthetic effect, is safe and effective, and excellent in clinical application prospect.

The present disclosure relates to a process for facilitating the identification of target chemicals which may be detected by means of an ion mobility spectrometer and a system for implementing the same. In an aspect of the disclosure, there is provided a process for determining the ratio of CI" to CI".OOH reactant ion species formed in a pentachloroethane doped ion mobility spectrometer operating in negative mode, said process comprising: i) introducing a sample comprising or consisting essentially of isoflurane into a pentachloroethane doped ion mobility spectrometer; ii) collecting data relevant to the detection of two isoflurane monomer ions formed following reaction with CI" and CI".OOH reactant ion species present in the pentachloroethane doped ion mobility spectrometer; and iii) determining the ratio of CI" to CI".OOH reactant ion species formed in the pentachloroethane doped ion mobility spectrometer based on an evaluation of the data collected.

The invention discloses inhalable isoflurane for pet use, and relates to the technical field of pet anesthesia. The inhalable isoflurane for the pet use has an isoflurane concentration of 0.5-1.5%, and is stored in a sealed tank. The inhalable isoflurane for the pet use enters the respiratory tract of a pet through a sealed mask, and mixes with oxygen so as to achieve anesthesia effects on the pet; and an exhaust gas filter device is arranged at the top of a respiratory mask. According to the invention, anesthesia is performed on a pet by using the inhalable isoflurane, of which the anesthesiadose and the lethal dose are greatly different, so that safe administration on the pet is ensured; and moreover, depth of anesthesia of the pet can be easily controlled so as to ensure relatively quick regaining of consciousness and fast recovery rate after the anesthesia. In addition, the inhalable isoflurane for the pet use is very convenient to use; and the inhalable isoflurane is stored in the sealed tank, so that the inhalable isoflurane is prevented from influence on preservation quality and subsequent use effects caused by photodegradation. Inhalation concentration of the inhalable isoflurane is controlled by an oxygen cylinder; and exhaust gas produced by the anesthesia is filtered by the exhaust gas filter device provided with activated carbon therein, so that people in the anesthesia range during the anesthesia on the pet is prevented from being affected by the anesthetic isoflurane.

The invention relates to a construction method and application of an animal model for detecting digestion and absorption characteristics of protein gel. The method comprises the steps: selecting male SD rats, placing each rat independently in a metabolism cage, adaptively feeding the rats with standard feed for one week, and performing fasting for 24 hours; starting to feed a protein gel sample for a period of time, feeding the rats at fixed time every day, freely drinking water, collecting residual samples at the same time in the morning next day, weighing, discarding, and feeding for another time; after 24 hours of fasting, feeding each rat with the same sample feeding time, taking out the rats after 3-4 hours, killing the rats with isoflurane, immediately collecting blood from aorta abdominalis, and collecting stomach digests and intestine digests from the stomach and the small intestine; and completing construction of the animal model for detecting the digestion characteristics of the protein gel. Compared with an intragastric administration method and a mixed feed method, the method is more suitable for researching the digestion and absorption characteristics of a protein gel food, and the influence of the structure of the protein gel food on the digestion and absorption characteristics can be researched through the method.

The invention relates to an establishment method and application of an animal model with nerve injury induced by HIV infection. The establishment method comprises a chimeric HIV virus inoculated in the abdominal cavity of a mouse or a chimeric HIV virus injected in the caudal vein of the mouse after the mouse is anesthetized by isoflurane, wherein the chimeric HIV virus has a nucleotide sequence as shown in SEQID NO.1. The animal model can greatly promote mechanism studying on nerve injury of patients caused by HIV, and can be used for pharmaceutical effect determination and pharmacological studying of anti-HIV related nerve injury medicines, especially has a great application value in the aspect of screening of new drugs.

The invention relates to an isoflurane based tranquilizing drug. The isoflurane based tranquilizing drug includes a medicament and a drug carrier, wherein the medicament is isoflurane. The drug carrier comprises a water-absorbing material and a shell. The water-absorbing material is used for carrying isoflurane, and the shell is used for coating the water-absorbing material to avoid isoflurane volatilization. The shell is provided with an opening for volatilizing isoflurane at the opening in the treatment process, and the opening is provided with a sealing device. The isoflurane based tranquilizing drug provided by the invention is an inhaled drug accepted by breathing, has fast tranquilizing speed and small side effect, and the drug subsides quickly after taking effect, and does not affect the normal life and work of drug users. In addition, the isoflurane based tranquilizing drug has low bioconversion rate and minimal influence to liver and kidney functions, and is still suitable for patients with incomplete liver and kidney functions.